TWI744215B - 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途 - Google Patents

檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途 Download PDF

Info

Publication number
TWI744215B
TWI744215B TW103138244A TW103138244A TWI744215B TW I744215 B TWI744215 B TW I744215B TW 103138244 A TW103138244 A TW 103138244A TW 103138244 A TW103138244 A TW 103138244A TW I744215 B TWI744215 B TW I744215B
Authority
TW
Taiwan
Prior art keywords
ferric citrate
patient
iron
content
average
Prior art date
Application number
TW103138244A
Other languages
English (en)
Chinese (zh)
Other versions
TW201609088A (zh
Inventor
安立奎 波拉多蘇
榮恩 班瑟爾
詹姆士Ｆ 三世 奧利維羅
Original Assignee
美商凱克斯生物製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商凱克斯生物製藥公司 filed Critical 美商凱克斯生物製藥公司
Publication of TW201609088A publication Critical patent/TW201609088A/zh
Application granted granted Critical
Publication of TWI744215B publication Critical patent/TWI744215B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TW103138244A 2013-11-04 2014-11-04 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途 TWI744215B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
US61/899,866 2013-11-04

Publications (2)

Publication Number Publication Date
TW201609088A TW201609088A (zh) 2016-03-16
TWI744215B true TWI744215B (zh) 2021-11-01

Family

ID=53005244

Family Applications (2)

Application Number Title Priority Date Filing Date
TW103138244A TWI744215B (zh) 2013-11-04 2014-11-04 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途
TW110136784A TW202203910A (zh) 2013-11-04 2014-11-04 檸檬酸鐵用於製備治療慢性腎病患者之貧血的藥劑之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110136784A TW202203910A (zh) 2013-11-04 2014-11-04 檸檬酸鐵用於製備治療慢性腎病患者之貧血的藥劑之用途

Country Status (15)

Country Link
US (3) US20160256486A1 (cg-RX-API-DMAC7.html)
EP (2) EP3747432A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016535780A (cg-RX-API-DMAC7.html)
KR (1) KR102392441B1 (cg-RX-API-DMAC7.html)
CN (1) CN105873583A (cg-RX-API-DMAC7.html)
AU (1) AU2014341975A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016009901A8 (cg-RX-API-DMAC7.html)
CA (1) CA2928200A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690926A1 (cg-RX-API-DMAC7.html)
HK (1) HK1223031A1 (cg-RX-API-DMAC7.html)
IL (1) IL245317A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016005734A (cg-RX-API-DMAC7.html)
SG (1) SG11201603091QA (cg-RX-API-DMAC7.html)
TW (2) TWI744215B (cg-RX-API-DMAC7.html)
WO (1) WO2015066593A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101665968B1 (ko) 2009-07-21 2016-10-13 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
KR20210131457A (ko) 2013-06-05 2021-11-02 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
ES2787218T3 (es) 2014-12-10 2020-10-15 Tricida Inc Polímeros de unión de protones para la administración oral
EP3452028A4 (en) 2016-05-06 2020-04-15 Tricida Inc. COMPOSITIONS AND METHOD FOR TREATING ACID-BASED DISORDERS
SG11202003451UA (en) 2017-11-03 2020-05-28 Tricida Inc Compositions for and method of treating acid-base disorders
CA3117071A1 (en) 2018-10-29 2020-05-07 Pharmacosmos Holding A/S Treating iron deficiency with ferric carboxymaltose
CN114286682A (zh) * 2019-02-09 2022-04-05 法码科思莫斯控股有限公司 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁
CN117999069A (zh) * 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130345303A1 (en) * 2012-06-21 2013-12-26 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (cg-RX-API-DMAC7.html) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
HUE025264T2 (en) * 2005-08-18 2016-02-29 Panion & Bf Biotech Inc Pharmaceutical-grade ferric citrate for medical use
HUE028029T2 (en) * 2006-01-30 2016-11-28 Panion & Bf Biotech Inc Method of treating chronic kidney disease
KR20080106506A (ko) * 2006-01-30 2008-12-08 글로보아시아 엘엘씨 만성 신장병의 치료 방법
KR101665968B1 (ko) 2009-07-21 2016-10-13 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
WO2012006473A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130345303A1 (en) * 2012-06-21 2013-12-26 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
CA2928200A1 (en) 2015-05-07
TW201609088A (zh) 2016-03-16
BR112016009901A8 (pt) 2020-04-14
EP3065734A4 (en) 2017-05-17
US20190307791A1 (en) 2019-10-10
JP2021073230A (ja) 2021-05-13
IL245317A0 (en) 2016-06-30
WO2015066593A1 (en) 2015-05-07
JP2019206562A (ja) 2019-12-05
CN105873583A (zh) 2016-08-17
JP2016535780A (ja) 2016-11-17
KR20160096597A (ko) 2016-08-16
EP3747432A1 (en) 2020-12-09
HK1223031A1 (zh) 2017-07-21
MX2016005734A (es) 2016-11-08
EA201690926A1 (ru) 2016-09-30
SG11201603091QA (en) 2016-05-30
TW202203910A (zh) 2022-02-01
EP3065734A1 (en) 2016-09-14
AU2014341975A1 (en) 2016-05-19
US20160256486A1 (en) 2016-09-08
JP6828100B2 (ja) 2021-02-10
US20250360167A1 (en) 2025-11-27
KR102392441B1 (ko) 2022-05-02

Similar Documents

Publication Publication Date Title
AU2018203205B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
TWI744215B (zh) 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途
CN108883085A (zh) 用铁化合物和柠檬酸盐化合物的组合物疗法
US20240041816A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
US20190269645A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
HK1210013B (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients